Literature DB >> 25364701

STAT3 Inhibition Induces Apoptosis in Cancer Cells Independent of STAT1 or STAT2.

Adetola Shodeinde1, Kalyani Ginjupalli1, H Dan Lewis1, Sheraz Riaz1, Beverly E Barton2.   

Abstract

Signal transducers and activators of transcription (STATs) were originally discovered as mediators of signal transduction. Persistent aberrant activation of STAT3 is part of the malignant phenotype of hormone-refractory prostate cancer and pancreatic cancer; this is thought to be mediated by homodimers of phosphorylated STAT3, which translocate to the nucleus. One consequence of persistently-activated STAT3 in malignant cells is that they depend upon it for survival. STAT3 is observed to heterodimerize with STAT1 and STAT2; however the contributions of STAT3:STAT1 and STAT3:STAT2 heterodimers to the survival of malignant cells have not been investigated in detail. Previously we reported that single-stranded oligonucleotides containing consensus STAT3 binding sequences (13410 and 13411) were more effective for inducing apoptosis in prostate cancer cells than antisense STAT3 oligonucleotides. Control oligonucleotides (scrambled sequences) had no effect. STAT3-inhibiting oligonucleotide 13410, but not scrambled-sequence oligonucleotides, induced apoptosis in pancreatic cancer cells as well. Here we report that 13410 and derivative olignucleotides induced apoptosis in STAT1-null and STAT2-null fibrosarcoma cell lines U3A and U6A, as well as in the parental fibrosarcoma cell line 2fTGH. The cell lines expressed constitutively-activated STAT3 and depended on its activity for survival. Forty-eight hr after transfection of 13410 or related oligonucleotides, significant apoptosis was observed in 2fTGH, U3A and U6A cells. Scrambled-sequence oligonucleotides had no effect on survival. These data indicate that neither STAT1 nor STAT2 play significant roles in the maintenance of these cells, and by extension that STAT3:STAT1 and STAT3:STAT2 heterodimers regulate a different set of genes from STAT3:STAT3 homodimers.

Entities:  

Year:  2013        PMID: 25364701      PMCID: PMC4215738     

Source DB:  PubMed          Journal:  J Mol Biochem        ISSN: 2241-0090


  37 in total

1.  Validating Stat3 in cancer therapy.

Authors:  James E Darnell
Journal:  Nat Med       Date:  2005-06       Impact factor: 53.440

2.  Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias.

Authors:  Noria Harir; Christian Pecquet; Marc Kerenyi; Karoline Sonneck; Boris Kovacic; Remy Nyga; Marie Brevet; Isabelle Dhennin; Valerie Gouilleux-Gruart; Hartmut Beug; Peter Valent; Kaiss Lassoued; Richard Moriggl; Fabrice Gouilleux
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

3.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

Authors:  R Catlett-Falcone; T H Landowski; M M Oshiro; J Turkson; A Levitzki; R Savino; G Ciliberto; L Moscinski; J L Fernández-Luna; G Nuñez; W S Dalton; R Jove
Journal:  Immunity       Date:  1999-01       Impact factor: 31.745

4.  Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression.

Authors:  Marina N Torrero; Xueqing Xia; Williams Henk; Shry Yu; Shulin Li
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

5.  Molecular characterization of human prostate carcinoma cell lines.

Authors:  Adrie van Bokhoven; Marileila Varella-Garcia; Christopher Korch; Widya U Johannes; E Erin Smith; Heidi L Miller; Steven K Nordeen; Gary J Miller; M Scott Lucia
Journal:  Prostate       Date:  2003-11-01       Impact factor: 4.104

6.  Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle.

Authors:  Minghao Zhong; Melissa A Henriksen; Kenji Takeuchi; Olaf Schaefer; Bin Liu; Johanna ten Hoeve; Zhiyong Ren; Xiang Mao; Xiaomin Chen; Ke Shuai; James E Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

7.  Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix.

Authors:  M A Guvakova; L A Yakubov; I Vlodavsky; J L Tonkinson; C A Stein
Journal:  J Biol Chem       Date:  1995-02-10       Impact factor: 5.157

8.  Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.

Authors:  Cecile Meier; Sylvia Hoeller; Caroline Bourgau; Petra Hirschmann; Juerg Schwaller; Philip Went; Stefano A Pileri; Andreas Reiter; Stephan Dirnhofer; Alexandar Tzankov
Journal:  Mod Pathol       Date:  2009-01-09       Impact factor: 7.842

9.  Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways.

Authors:  Marcus Lehnhardt; Ludger Klein-Hitpass; Cornelius Kuhnen; Heinz Herbert Homann; Adrien Daigeler; Hans Ulrich Steinau; Sonja Roehrs; Laura Schnoor; Lars Steinstraesser; Oliver Mueller
Journal:  BMC Cancer       Date:  2005-07-07       Impact factor: 4.430

10.  MicroRNA-145 targets YES and STAT1 in colon cancer cells.

Authors:  Lea H Gregersen; Anders B Jacobsen; Lisa B Frankel; Jiayu Wen; Anders Krogh; Anders H Lund
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more
  4 in total

1.  Growth-Suppressive and Apoptosis-Inducing Effects of Tetrandrine in SW872 Human Malignant Liposarcoma Cells via Activation of Caspase-9, Down-Regulation of XIAP and STAT-3, and ER Stress.

Authors:  Mohammed Samsuzzaman; Byeong-Churl Jang
Journal:  Biomolecules       Date:  2022-06-17

2.  New STAT3-FOXL2 pathway and its function in cancer cells.

Authors:  Yangyang Han; Jun Wu; Weiwei Yang; Di Wang; Tianliang Zhang; Min Cheng
Journal:  BMC Mol Cell Biol       Date:  2019-06-20

3.  STAT3 as a target for sensitizing prostate cancer cells to irradiation.

Authors:  Qu Zhang; Xiao-Mei Zhou; Shao-Zhong Wei; Dian-Sheng Cui; Kang-Li Deng; Gai Liang; Yan Luo; Bo Luo; Xin-Jun Liang
Journal:  J Radiat Res       Date:  2022-03-17       Impact factor: 2.724

4.  Transmembrane and Ubiquitin-Like Domain Containing 1 Protein (TMUB1) Negatively Regulates Hepatocellular Carcinoma Proliferation via Regulating Signal Transducer and Activator of Transcription 1 (STAT1).

Authors:  Yin Chen; Hangwei Fu; Yida Zhang; Ping Chen
Journal:  Med Sci Monit       Date:  2019-12-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.